Psychedelic Drug Treatments Are Just Beginning to Capture Sizable Investor Interest

Psychedelic substances are gaining traction as a treatment for mental illnesses, creating sizable opportunities for investors. In fact, according to The New York Times, Johns Hopkins Medicine announced the launch of the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin mushrooms for a range of mental health problems, including anorexia, addiction and depression. The center is the first of its kind in the country, established with $17 million in commitments. It’s opening a wide range of opportunity for companies that have already established launching cannabis products including The Yield Growth Corp.(CSE:BOSS) (OTC:BOSQF), Canopy Growth Corporation (TO:WEED) (NYSE:CGC), Green Growth Brands Inc.(CSE:GGB) (OTC:GGBXF),Charlotte’s Web Holdings Inc. (CN:CWEB)(OTC:CWBHF), and Aurora Cannabis Inc.(NYSE:ACB)(TO:ACB). The Yield Growth Corp.(CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS:The Yield Growth Corp. just announced that on September 14, 2019, it entered into an agreement with Absolem Health Corp., 100% owner of One Up Pure Energy Inc., ... Click here to view full article